integriertes Sozialpädiatrisches Zentrum im Dr. von Haunerschen Kinderspital – iSPZ Hauner MUC – Munich University Center for Children with Medical and Developmental Complexity
  1. Startseite LMU Klinikum
  2. iSPZ
  3. Forschung und Lehre
  4. Studien

Studien

Laufende Studien – Kooperation LMU

  • Wertigkeit einer Gruppe von Biomarkern in der Differentialdiagnose von Kindern mit einer ersten demyelinisierenden Erkrankung des ZNS. Multicenter

    Multiple Sklerose

  • Connect (109 MS306) Open-Label, Randomized, Multicenter, Multiple-Dose,Active-Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children

    Multiple Sklerose

  • SNT-III-012 - A Phase III Double blind, Randomized, Placebo Controlled Study assessing the Efficacy, Safety and Tolerability of Idebenone in Patients with Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids

  • DSC/14/2357/48 - Givinostat Randomised, double blind, placebo controlled, multicentre study to evaluate the efficacy and safety of givinostat in ambulant patients with Duchenne Muscular Dystrophy

  • ATX-MTM-009 INCEPTUS - A Prospective, Non-Interventional Clinical Assessment Study in X-Linked Myotubular Myopathy (XLMTM) Subjects Aged 3 Years and Younger

  • ATX-MTM-002 ASPIRO A Phase 1/2, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT132, an AAV8-Delivered Gene

  • HINE (ISIS 396443-CS11) An Open-Label Extension Study for Patients With Spinal Muscular Atrophy Who Previously Participated in Investigational Studies of ISIS 396443

  • CAT-1004-304: POLARIS DMD single global Phase 3 trial called POLARIS DMD in Duchenne to evaluate the efficacy and safety of edasalonexent

  • A Randomized, Active-Controlled, Open-Label, Flexible-Dose Study to Assess the Safety

    and Tolerability of Topiramate as Monotherapy Compared With Levetiracetam as

    Monotherapy in Pediatric Subjects With New or Recent-Onset Epilepsy

  • moma – modules on migraine activity

    Strukturierte multimodale Frühintervention für Kinder mit Migräne im Alter von 6-11 Jahren

  • Deutsches FASD KOMPETENZZENTRUM Bayern